Managing depressive and anxiety disorders with escitalopram

Expert Opinion on Pharmacotherapy
Michael E Thase

Abstract

This article reviews escitalopram, the S-stereoisomer of the racemic compound citalopram, and a highly selective and potent member of the selective serotonin re-uptake inhibitor class of antidepressants. Escitalopram has a straightforward pharmacokinetic profile, little effect on hepatic metabolism, and is relatively safe in overdose. Similar to other members of the selective serotonin re-uptake inhibitor class, escitalopram (10-20 mg/day) is a well-tolerated and effective treatment of major depressive disorder. Although relatively few head-to-head comparative studies with other antidepressants have been published, pooled analyses of studies using citalopram as the active comparator suggest a modest advantage for the stereoisomer. This advantage, which is more apparent among patients with greater symptom levels, may be attributable to a greater than predicted potency compared with citalopram, presumably as a result of the greater effect of escitalopram at the allosteric binding site of the serotonin transporter. Results of two published studies versus venlafaxine also suggest better tolerability in the context of comparable efficacy. Escitalopram is also approved for the treatment of generalised anxiety disorder (in the US) and...Continue Reading

References

Apr 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·S A Montgomery, M Asberg
Jan 1, 1994·International Clinical Psychopharmacology·S A MontgomeryD Nutt
Dec 16, 2000·The British Journal of Psychiatry : the Journal of Mental Science·N FreemantleP Young
Mar 7, 2001·The British Journal of Psychiatry : the Journal of Mental Science·M E ThaseR L Rudolph
Aug 21, 2001·Journal of Affective Disorders·K DemyttenaereE Van Ganse
May 1, 2002·International Clinical Psychopharmacology·A WadeK Bang Hedegaard
May 2, 2002·The British Journal of Psychiatry : the Journal of Mental Science·David SmithIan Anderson
May 10, 2002·The Journal of Clinical Psychiatry·William J BurkeAnjana Bose
Dec 7, 2002·BMJ : British Medical Journal·Nicholas A Buckley, Peter R McManus
Jun 21, 2003·International Clinical Psychopharmacology·Ulla M LepolaElin Heldbo Reines
Dec 9, 2003·The Journal of Clinical Psychiatry·Stephen M StahlDayong Li
Dec 11, 2003·Psychotherapy and Psychosomatics·Staffan Svensson, Peter R Mansfield
Jan 28, 2004·The Journal of Clinical Psychiatry·Mark Hyman RapaportHongjie Zheng
Jan 31, 2004·Pharmacology, Biochemistry, and Behavior·Connie Sánchez, Mads Kreilgaard
Apr 29, 2004·The Annals of Pharmacotherapy·Michiel E H HemelsThomas R Einarson
May 8, 2004·CNS Spectrums·C Lindsay DeVane, David W Boulton
May 26, 2004·Psychopharmacology·Connie SánchezClaus Braestrup
Jun 1, 2004·The American Journal of Psychiatry·Karen Dineen WagnerWilliam E Heydorn
Sep 16, 2004·The Journal of Clinical Psychiatry·Robert J BielskiChung-Chi Chang
Oct 9, 2004·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Ian C K WongMacey L Murray
Oct 16, 2004·Depression and Anxiety·Wei ZhangJonathan R T Davidson
Dec 4, 2004·The International Journal of Neuropsychopharmacology·David S Baldwin, Claire Polkinghorn
Jan 14, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jeffery A LiebermanMartin B Keller
Jan 27, 2005·The Journal of Clinical Psychiatry·David V SheehanUNKNOWN Paxil CR Panic Disorder Study Group
Feb 8, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Fenghua ChenOve Wiborg
Feb 11, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Mostafa El MansariNasser Haddjeri
Mar 2, 2005·The British Journal of Psychiatry : the Journal of Mental Science·Siegfried KasperRico Nil
Mar 8, 2005·PharmacoEconomics·José-Luis FernandezClément Francois
Apr 7, 2005·International Clinical Psychopharmacology·Anders Gersel Pedersen

❮ Previous
Next ❯

Citations

Mar 25, 2011·Neuropsychiatric Disease and Treatment·Mazen K Ali, Raymond W Lam
Jan 24, 2012·Expert Opinion on Pharmacotherapy·Sara Gibiino, Alessandro Serretti
Apr 18, 2008·Expert Review of Neurotherapeutics·Cyril Höschl, Jaromír Svestka
Jan 1, 2006·International Journal of Psychiatry in Clinical Practice·Raymond W Lam
Jan 1, 2007·International Journal of Psychiatry in Clinical Practice·Naomi A Fineberg
Jun 12, 2012·Life Sciences·Ravid DoronMoshe Rehavi
Oct 21, 2009·Journal of Clinical Pharmacology·Yuyan JinRobert R Bies
Oct 4, 2006·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Christoffer BundgaardJohan Gabrielsson
Sep 23, 2006·Journal of Pharmacological and Toxicological Methods·Christoffer BundgaardArne Mørk
May 9, 2018·Journal of Molecular Neuroscience : MN·Ravid DoronMoshe Rehavi
Mar 16, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Dan AtarVictor L Serebruany
Dec 22, 2006·Expert Review of Neurotherapeutics·Margarita García-AmadorEduard Vieta
Sep 7, 2006·CNS Drugs·Sohita DhillonGreg L Plosker
Feb 8, 2020·Molecular Biotechnology·Emiliano Tesoro-CruzVilma Carolina Bekker-Méndez
Aug 6, 2021·Biological & Pharmaceutical Bulletin·Lobna A AbdelwahabAiman S El-Khatib

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.